Top Markets
#1 SODAX SODAX +58.16%
#2 龙虾 (Lobster) 龙虾 (Lobster) +37.41%
#3 Cortex Cortex +32.76%
#4 DexNet DexNet +23.20%
#5 Pons Pons +21.75%
#6 Akedo Akedo +20.11%
#7 wojak wojak +18.55%
#8 MANTRA MANTRA +14.88%
#9 OpenEden OpenEden +14.07%
#10 APEX APEX +13.93%
Coin of the day
SODAX SODAX
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Chinook Therapeutics, Inc. Chinook Therapeutics, Inc.

Chinook Therapeutics, Inc.

KDNY
Clasificación en acciones #7141
Chinook Therapeutics, Inc., a biotechnology enterprise in the clinical... Chinook Therapeutics, Inc., a biotechnology enterprise in the clinical development phase, is dedicated to the identification, progression, and market introduction of precise medical treatments for kidney-related conditions. The company's primary therapeutic candidate, atrasentan, is an endothelin receptor antagonist currently in Phase III clinical trials. This drug aims to treat IgA nephropathy and various other glomerular diseases characterized by proteinuria. Beyond its lead program, Chinook's investigational pipeline includes BION-1301, an anti-APRIL monoclonal antibody, which is presently being evaluated in a Phase I/II study for IgA nephropathy. Another promising candidate is CHK-336, an oral small molecule designed to inhibit LDHA, intended for patients with primary hyperoxaluria. The firm also maintains active research initiatives exploring solutions for other uncommon and severe chronic kidney ailments. Chinook Therapeutics, Inc. is based in Seattle, Washington.
Precio por acción
$40.39
Última sincronización: 2023-08-18
Capitalización bursátil
$1.70B
Cambio (1 día)
0.00%
Cambio (1 año)
0.00%
País
US
Comercio Chinook Therapeutics, Inc. (KDNY)

Categoría

Healthcare
Ingresos de Chinook Therapeutics, Inc. (KDNY)
Ingresos en Aug 2026 TTM: 0
Según los últimos informes financieros de Chinook Therapeutics, Inc., los ingresos actuales de la empresa (TTM) son 0. En 2026, la empresa obtuvo unos ingresos de 0 igual a los ingresos del año 2026, que fueron de 0. Los ingresos representan la cantidad total que una empresa genera por la venta de bienes o servicios. A diferencia de las ganancias, no se restan los gastos.
Historial de ingresos de Chinook Therapeutics, Inc. desde 2026 hasta 2026
Ingresos al final de cada año
Año Ingresos Cambiar
Not enough data for the provided dates.
Ingresos de empresas similares o competidoras
Empresa Ingresos Diferencia de ingresos País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH